Understanding Metabolic Reprogramming in Platinum Resistant Ovarian Cancer

了解铂类耐药卵巢癌的代谢重编程

• 批准号: 10485428
• 负责人: Daniela E Matei
• 金额: --
• 依托单位: JESSE BROWN VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-10-01 至 2026-09-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10485428
• 关键词: Address; Award; Biological Assay; Biological Markers; Breast Cancer Cell; Cancer Patient; Carbon; Cause of Death; Cell Death; Cell Death Induction; Cell Line; Cells; Cellular biology; Cessation of life; Chemicals; Chemoresistance; Clinical; Clinical Management; Collaborations; Collecting Cell; Colorectal Cancer; Consumption; DNA Damage; DNA Repair Pathway; Data; Dependence; Development; Diagnosis; Disease Progression; Disease Resistance; Disease remission; Energy-Generating Resources; Enzymes; Fatal Outcome; Fatty Acids; Fatty-acid synthase; Fluorescence; Generations; Genetic; Glucose; Glutamine; Glutathione; Glycolysis; Goals; Human; Image; Imaging Device; Imaging Techniques; Immunocompetent; Immunotherapy; Induction of Apoptosis; Lipid Peroxidation; Lipids; Malignant Epithelial Cell; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of ovary; Measurement; Measures; Mediating; Membrane Lipids; Membrane Transport Proteins; Metabolic; Metabolism; Methods; Modeling; Molecular; Molecular and Cellular Biology; Monitor; Multiomic Data; Mus; Organoids; Ovarian; Ovarian Serous Adenocarcinoma; Oxidative Stress; Pathway interactions; Patients; Peroxides; Phenotype; Platinum; Pre-Clinical Model; Predisposition; Process; Reactive Oxygen Species; Recurrence; Recurrent Malignant Neoplasm; Recurrent disease; Reporting; Research Personnel; Resistance; Resource Sharing; Resources; Sampling; Serous; Systems Biology; Technology; Testing; Therapeutic; Treatment Efficacy; Tumor Debulking; Unsaturated Fatty Acids; Woman; Work; biomarker driven; cancer cell; cancer recurrence; cancer stem cell; chemotherapy; clinical development; clinically relevant; desaturase; digital; fatty acid oxidation; imaging modality; indexing; inhibitor; kinase inhibitor; lipid biosynthesis; lipidomics; metabolic abnormality assessment; metabolic imaging; molecular imaging; mouse model; multidisciplinary; multimodality; neoplastic cell; new therapeutic target; novel; novel strategies; novel therapeutic intervention; ovarian neoplasm; oxaliplatin; oxidized lipid; patient derived xenograft model; pre-clinical; prevent; prognostic assays; refractory cancer; response; small molecule; spectroscopic imaging; standard care; targeted agent; targeted treatment; therapeutic biomarker; therapy resistant; transcriptomics; treatment strategy; tumor; two-photon

PROJECT SUMMARY This Collaborative Merit Award application (CMA), consisting of three projects (CMA1-3), addresses a critical challenge in the clinical management of ovarian cancer. The most common and most lethal subtype of ovarian cancer is high-grade serous ovarian carcinoma (HGSOC). Standard treatment for HGSOC combines surgical cytoreduction with platinum-based chemotherapy. The treatment is initially successful in achieving remission. However, cancer recurs in most women. Patients with recurrent disease may continue to respond to additional rounds of platinum but will ultimately develop platinum resistance (PtR). At that point, the tumor is typically resistant to other treatment strategies. The key to increasing survival in HGSOC is to prevent the development of PtR or identify alternative means of targeting resistant tumors. The main goal of this interdisciplinary and collaborative project is to identify novel targets and biomarkers of therapeutic efficacy for HGSOC. This requires a better understanding of the mechanisms that either select for, or promote transformation of, HGSOC cells to an aggressive, therapy-resistant phenotype. While previous studies on PtR have focused on DNA repair pathways or altered membrane transporters, new concepts support the hypothesis that a key contributor to PtR is the reprogramming of cancer cells into a less differentiated and metabolically adaptable state. This collaborative proposal by three established ovarian cancer researchers will leverage their interdisciplinary expertise and rich resources to define new molecular mechanisms of PtR in ovarian cancer. CMA1 will utilize deep imaging to define clinically-relevant biomarkers of PtR while digital spatial profiling and systems biology will be used to identify molecular pathways underlying PtR. Preclinical immunocompetent mouse models will be used to test potential targeted therapies discovered in CMA1,2&3. CMA2 will study metabolic adaptation associated with the emergence of PtR focusing on a shift to fatty acid oxidation in resistant HGSOC cells and tumors. CMA2 will use resources shared with CMA1&3 and cellular biology and novel single cell metabolic imaging to define unique metabolic dependencies of PtR HGSOC. As resistant tumors are highly susceptible to death induced by oxidized lipid membranes, mechanisms of ferroptosis will be examined in PtR models treated with novel metabolism targeting agents, which will be tested together with CMA1. CMA3 will define the emergent de-differentiated phenotype in recurrent HGSOC through transcriptomic analysis of patient tumors collected at various stages of disease progression. By defining molecular pathways that lead to cellular de-differentiation, we will reveal new vulnerabilities that can be therapeutically exploited using small molecules, kinase inhibitors, and cell-based immune therapy approaches Multi-omics data, patient derived organoids, and PDX models will provide valuable shared resource for collaborative projects in CMA1&2. The overarching hypothesis of CMA2 is that metabolic reprogramming is a key and necessary step in the development of PtR. We speculate that this shift is initiated through altered oxidative status in cancer cells, due to DNA injuries inflicted by platinum. To test the hypothesis, we will determine whether Pt-R cancer cells and tumors undergo a metabolic shift to fatty acid oxidation caused by increased generation of reactive oxygen species (ROS). We will measure intracellular ROS, glucose and lipid consumption and quantify expression and function of key lipid transporters and rate limiting enzymes regulating lipogenesis. Molecular findings will be validated by using high content stimulated Raman scattering (SRS) metabolic imaging and multimodal SRS / two-photon excitation fluorescence (TPEF). We will test whether by blockade of key enzymes or transporters involved in metabolic reprogramming can overcome the state of resistance and whether these inhibitors induce cell death in PtR cells through ferroptosis. Mechanistic understanding of this process will lead to new treatment opportunities for fatal PtR HGSOC and other cancers.

项目总结 此协作优秀奖申请(CMA)由三个项目(CMA1-3)组成，解决了一个关键问题 卵巢癌临床治疗中的挑战。卵巢癌最常见和最致命的亚型 癌症是高级别浆液性卵巢癌(HGSOC)。HGSOC合并外科手术的标准治疗 以铂为基础的化疗使细胞减少。这种治疗最初在实现缓解方面是成功的。 然而，大多数女性的癌症会复发。复发疾病的患者可能会继续对其他 但最终会形成铂金阻力(PTR)。在这一点上，肿瘤通常是 对其他治疗策略具有抗药性。提高HGSOC存活率的关键是防止发展 或寻找靶向耐药肿瘤的替代方法。这一跨学科和 合作项目是寻找治疗HGSOC疗效的新靶点和生物标记物。这需要 更好地理解选择或促进HGSOC细胞转化为 一种侵略性的、对治疗有抵抗力的表型。虽然以前对PTR的研究主要集中在DNA修复上 途径或改变的膜转运蛋白，新的概念支持这一假设，即PTR的关键贡献者 是将癌细胞重新编程到较低分化和新陈代谢适应状态。这 由三位成熟的卵巢癌研究人员提出的合作提案将利用他们的跨学科 专业知识和丰富的资源，以确定卵巢癌PTR的新分子机制。CMA1将利用 深度成像以确定PTR的临床相关生物标记物，同时数字空间剖面图和系统生物学 将被用来确定PTR的分子途径。临床前免疫活性小鼠模型将是 用于测试在CMA1、2和3中发现的潜在靶向治疗。CMA2将研究代谢适应 与PTR的出现有关，集中在耐药的HGSOC细胞向脂肪酸氧化的转变和 肿瘤。CMA2将使用与CMA1&3共享的资源、细胞生物学和新的单细胞代谢 成像以确定PTR HGSOC的独特代谢依赖性。因为耐药肿瘤对 氧化脂质膜引起的死亡，铁性下垂的机制将在PTR治疗模型中进行研究 新型新陈代谢靶向剂，将与CMA1一起进行测试。CMA3将定义新的 复发性HGSOC的去分化表型通过对收集于 疾病发展的不同阶段。通过定义导致细胞去分化的分子途径， 我们将揭示新的漏洞，这些漏洞可以通过使用小分子、激酶抑制剂、 基于细胞的免疫治疗方法--多组学数据、患者衍生的有机化合物和PDX模型将 为CMA1和CM2中的协作项目提供有价值的共享资源。 CMA2的首要假设是新陈代谢重新编程是 PTR的发展。我们推测，这种转变是通过改变癌细胞的氧化状态而启动的， 铂对DNA造成的损伤。为了验证这一假设，我们将确定铂-R癌细胞和 由于活性氧生成的增加，肿瘤经历了向脂肪酸氧化的代谢转变 种(ROS)。我们将测量细胞内ROS，葡萄糖和脂肪的消耗，并量化表达和 调节脂肪生成的关键脂质转运体和限速酶的功能。分子研究结果将会是 利用高含量受激拉曼散射(SRS)代谢成像和多峰SRS/ 双光子激发荧光(TPEF)。我们将测试是否通过阻断关键酶或转运蛋白 参与代谢重新编程可以克服抵抗状态，以及这些抑制剂是否会诱导 铁性下垂引起的PTR细胞死亡。从机理上理解这一过程将导致新的治疗方法 致命性PTR、HGSOC和其他癌症的机会。